Decheng Capital Global Life Sciences Fund IV, L.P. bought $20.0M of Aardvark Therapeutics (AARD)
Executed Feb 14 2025, disclosed Feb 19 2025, 5 days later.
Over the 21 trading sessions from the disclosed entry session (Feb 19 2025), the stock returned -29.2% (delay-adjusted); from the execution session (Feb 14 2025), -35.4%. Derived: entry at the session's open, exit at the close 20 sessions later.
Decheng Capital Global Life Sciences Fund IV, L.P. (10% owner) filed 1 Form 4 report as a reporting entity in the past 24 months (1 purchase, 0 sales), most often in Aardvark Therapeutics, Inc. (AARD). Across 1 priced purchase filing, the average 21-session return was -35.4% from execution and -29.2% from disclosure (delay-adjusted; derived). The largest single filing was $20.0M of AARD (1,250,000 sh across 2 lots, as filed), executed Feb 14 2025.
Healthcare · Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate inna…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→